ECSP22066670A - 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso - Google Patents

2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso

Info

Publication number
ECSP22066670A
ECSP22066670A ECSENADI202266670A ECDI202266670A ECSP22066670A EC SP22066670 A ECSP22066670 A EC SP22066670A EC SENADI202266670 A ECSENADI202266670 A EC SENADI202266670A EC DI202266670 A ECDI202266670 A EC DI202266670A EC SP22066670 A ECSP22066670 A EC SP22066670A
Authority
EC
Ecuador
Prior art keywords
quinazolin
piperazin
methoxyphenyl
trifluoromethyl
fluoro
Prior art date
Application number
ECSENADI202266670A
Other languages
English (en)
Inventor
Bertran Jordi Carles Ceron
Thomas Goldner
Helmut Buschmann
Original Assignee
Aic246 Ag Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag Co Kg filed Critical Aic246 Ag Co Kg
Publication of ECSP22066670A publication Critical patent/ECSP22066670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la nueva 3,4-dihidroquinazolina, 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acetato de sodio monohidrato, métodos para su preparación, así como composiciones farmacéuticas que contienen dicha 3,4-dihidroquinazolina. Dicho compuesto es particularmente útil para el tratamiento y prevención de enfermedades asociadas con citomegalovirus (CMV), particularmente citomegalovirus humano (HCMV).
ECSENADI202266670A 2020-02-27 2022-08-24 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso ECSP22066670A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159709 2020-02-27

Publications (1)

Publication Number Publication Date
ECSP22066670A true ECSP22066670A (es) 2022-12-30

Family

ID=69742712

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202266670A ECSP22066670A (es) 2020-02-27 2022-08-24 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso

Country Status (21)

Country Link
US (1) US20230219900A1 (es)
EP (1) EP4110469A1 (es)
JP (1) JP7579350B2 (es)
KR (1) KR20220147655A (es)
CN (1) CN115427111A (es)
AR (1) AR121440A1 (es)
AU (1) AU2021225364B2 (es)
BR (1) BR112022016906A2 (es)
CA (1) CA3169473A1 (es)
CL (1) CL2022002290A1 (es)
CO (1) CO2022012017A2 (es)
CU (1) CU20220047A7 (es)
EC (1) ECSP22066670A (es)
IL (1) IL295633A (es)
MX (1) MX2022010440A (es)
MY (1) MY210486A (es)
PE (1) PE20230347A1 (es)
PY (1) PY2116987A (es)
TW (1) TWI886221B (es)
UY (1) UY39098A (es)
WO (1) WO2021170879A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119731157A (zh) * 2022-08-15 2025-03-28 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
PY24113872A (es) 2023-12-21 2025-07-29 Aic 246 Ag & Co Kg Sales diastereoméricas de aminoalchohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica.-

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
TW202140454A (zh) 2021-11-01
CL2022002290A1 (es) 2023-02-03
MX2022010440A (es) 2022-10-18
CU20220047A7 (es) 2023-04-10
TWI886221B (zh) 2025-06-11
PY2116987A (es) 2021-12-01
JP7579350B2 (ja) 2024-11-07
KR20220147655A (ko) 2022-11-03
US20230219900A1 (en) 2023-07-13
JP2023519809A (ja) 2023-05-15
AU2021225364A1 (en) 2022-10-13
CN115427111A (zh) 2022-12-02
CO2022012017A2 (es) 2022-11-18
AR121440A1 (es) 2022-06-08
UY39098A (es) 2021-09-30
AU2021225364B2 (en) 2024-11-28
WO2021170879A1 (en) 2021-09-02
BR112022016906A2 (pt) 2022-12-06
IL295633A (en) 2022-10-01
NZ792571A (en) 2025-07-25
PE20230347A1 (es) 2023-03-02
EP4110469A1 (en) 2023-01-04
CA3169473A1 (en) 2021-09-02
MY210486A (en) 2025-09-25

Similar Documents

Publication Publication Date Title
JOP20210307A1 (ar) مثبطات جسيم التهابي nlrp3
ECSP22066670A (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
BRPI0409109A (pt) novos compostos
JP2013544893A5 (es)
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
NZ607580A (en) N-heteroaryl compounds
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
WO2010129057A8 (en) Tetracycline compounds
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
MX2024002696A (es) Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central.
MY210500A (en) Potassium salt of 2-[(4s)-8-f1uoro-2-4-(-3-methoxyphenyl)piperazin-1 -yl]-3-[2- methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl] acetic acid
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
GEAP202416566A (en) Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl) piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions
PA8661101A1 (es) Compuestos antihelminticos
CU20220049A7 (es) Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden
CL2004000810A1 (es) Compuesto derivado de acido hidroxamico de formula definida; composicion farmaceutica que comprende al compuesto y uso del compuesto para preparar medicamentos utiles para tratar trastornos hiperproliferativos.